Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-04-29 4:08 pm Purchase | 13D | BENITEC BIOPHARMA INC BNTC | SUVRETTA CAPITAL MANAGEMENT LLC | 1,700,850 19.99% | 1,438,007 (+547.10%) | View |
| 2024-04-15 4:38 pm Purchase | 13G | CONTINEUM THERAPEUTICS INC CL CTNM | SUVRETTA CAPITAL MANAGEMENT LLC | 1,720,000 9.3% | 1,720,000 (New Position) | View |
| 2024-02-13 5:28 pm Purchase | 13G | SPYRE THERAPEUTICS, INC SYRE | SUVRETTA CAPITAL MANAGEMENT LLC | 412,395 1% | 412,395 (New Position) | View |
| 2024-02-13 5:27 pm Sale | 13G | PROKIDNEY CORP PROK | SUVRETTA CAPITAL MANAGEMENT LLC | 4,725,348 7% | -1,554,827 (-24.76%) | View |
| 2024-02-13 5:26 pm Purchase | 13G | MEREO BIOPHARMA GROUP PLC ADR MREO | SUVRETTA CAPITAL MANAGEMENT LLC | 36,854,190 5.3% | 32,000 (+0.09%) | View |
| 2024-02-13 5:23 pm Purchase | 13G | KURA ONCOLOGY INC KURA | SUVRETTA CAPITAL MANAGEMENT LLC | 7,472,343 9.99% | 1,095,528 (+17.18%) | View |
| 2024-02-13 5:19 pm Purchase | 13G | KALVISTA PHARMACEUTICALS INC C KALV | SUVRETTA CAPITAL MANAGEMENT LLC | 2,684,005 7.8% | 887,626 (+49.41%) | View |
| 2024-02-13 5:16 pm Purchase | 13G | BENITEC BIOPHARMA INC BNTC | SUVRETTA CAPITAL MANAGEMENT LLC | 262,843 9.99% | 262,843 (New Position) | View |
| 2024-02-13 5:08 pm Purchase | 13G | BIOHAVEN RESH LTD. USD COM SHS BHVN | SUVRETTA CAPITAL MANAGEMENT LLC | 4,572,836 5.7% | 723,898 (+18.81%) | View |
| 2024-02-13 12:29 pm Sale | 13G | ARCUTIS BIOTHERAPEUTICS INC CO ARQT | SUVRETTA CAPITAL MANAGEMENT LLC | 9,534,837 9.99% | -57,375 (-0.60%) | View |
| 2024-02-13 12:24 pm Purchase | 13G | 89BIO INC ETNB | SUVRETTA CAPITAL MANAGEMENT LLC | 4,888,434 5.2% | 80,060 (+1.67%) | View |
| 2024-02-13 12:16 pm Purchase | 13G | SUTRO BIOPHARMA INC STRO | SUVRETTA CAPITAL MANAGEMENT LLC | 5,778,188 9.5% | 213,089 (+3.83%) | View |
| 2024-02-13 12:13 pm Purchase | 13G | MARINUS PHARMACEUTICALS INC MRNS | SUVRETTA CAPITAL MANAGEMENT LLC | 5,463,641 9.99% | 491,981 (+9.90%) | View |
| 2024-02-13 12:08 pm Purchase | 13G | FULCRUM THERAPEUTICS INC FULC | SUVRETTA CAPITAL MANAGEMENT LLC | 5,518,881 8.9% | 1,244,078 (+29.10%) | View |
| 2024-02-13 12:00 pm Purchase | 13G | EYEPOINT PHARMACEUTICALS, INC. EYPT | SUVRETTA CAPITAL MANAGEMENT LLC | 4,774,389 9.99% | 1,363,179 (+39.96%) | View |
| 2024-02-13 11:55 am Purchase | 13G | KEZAR LIFE SCIENCES INC KZR | SUVRETTA CAPITAL MANAGEMENT LLC | 7,167,591 9.9% | 3,663,327 (+104.54%) | View |
| 2024-02-13 11:50 am Purchase | 13G | ARCELLX INC ACLX | SUVRETTA CAPITAL MANAGEMENT LLC | 2,435,974 5% | 85,641 (+3.64%) | View |
| 2024-02-13 11:44 am Purchase | 13G | TERNS PHARMACEUTICALS INC TERN | SUVRETTA CAPITAL MANAGEMENT LLC | 5,837,126 9.5% | 2,388,851 (+69.28%) | View |
| 2024-02-05 4:43 pm Purchase | 13G | COGENT BIOSCIENCES INC COGT | SUVRETTA CAPITAL MANAGEMENT LLC | 5,481,034 6.4% | 5,481,034 (New Position) | View |
| 2023-10-30 5:03 pm Purchase | 13G | ARCUTIS BIOTHERAPEUTICS INC CO ARQT | SUVRETTA CAPITAL MANAGEMENT LLC | 9,592,212 9.99% | 9,592,212 (New Position) | View |